NeuroTrauma Sciences reported data on its novel neuroactive small molecule NTS-105 in a poster presentation at the 39th Annual Symposium of the National Neurotrauma Society in Atlanta, GA.

NeuroTrauma Sciences today provided an update on the development of its lead drug candidates NTS-104 and NTS-105 in traumatic brain injury.

Preclinical research to focus on sleep, inflammation and efficacy of the NTS compound NTS-104 in TBI

The study demonstrated the ability of NTS-105 to reduce cell death at a wide range of concentrations in preclinical models of TBI.

Dr. Parry will discuss recent advances in the development of novel neurosteroids for the treatment of traumatic brain injury.